ASH 2023 | Optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma
Ariel Grajales-Cruz
• 9 Dec 2023
Ariel Grajales-Cruz, MD, Moffitt Cancer Center, Tampa, FL, explores the challenge of sequencing immunotherapies for myeloma treatment in light of advancements in CAR T-cell therapy and bispecific antibodies targeting BCMA and GPRC5D. Further data is required to determine the most effective sequence of immunotherapeutic interventions for achieving optimal patient outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: Amgen, Sanofi
Board of Directors/Advisory Committee: Sanofi, Cellectar, Janssen
